遗传性肾细胞癌:年龄是基因检测的独立标准吗?来自拉丁美洲转诊中心的大队列研究。

IF 1.9 Q3 ONCOLOGY Journal of Kidney Cancer and VHL Pub Date : 2023-01-01 DOI:10.15586/jkcvhl.v10i3.242
Tomás Carminatti, Patricio Aitor García Marchiñena, Ignacio Pablo Tobia González, Valeria de Miguel, Marcelo Martín Serra, Pablo Germán Kalfayan, Alberto Manuel Jurado
{"title":"遗传性肾细胞癌:年龄是基因检测的独立标准吗?来自拉丁美洲转诊中心的大队列研究。","authors":"Tomás Carminatti,&nbsp;Patricio Aitor García Marchiñena,&nbsp;Ignacio Pablo Tobia González,&nbsp;Valeria de Miguel,&nbsp;Marcelo Martín Serra,&nbsp;Pablo Germán Kalfayan,&nbsp;Alberto Manuel Jurado","doi":"10.15586/jkcvhl.v10i3.242","DOIUrl":null,"url":null,"abstract":"<p><p>Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"10 3","pages":"17-22"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404984/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center.\",\"authors\":\"Tomás Carminatti,&nbsp;Patricio Aitor García Marchiñena,&nbsp;Ignacio Pablo Tobia González,&nbsp;Valeria de Miguel,&nbsp;Marcelo Martín Serra,&nbsp;Pablo Germán Kalfayan,&nbsp;Alberto Manuel Jurado\",\"doi\":\"10.15586/jkcvhl.v10i3.242\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.</p>\",\"PeriodicalId\":44291,\"journal\":{\"name\":\"Journal of Kidney Cancer and VHL\",\"volume\":\"10 3\",\"pages\":\"17-22\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404984/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Kidney Cancer and VHL\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15586/jkcvhl.v10i3.242\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Kidney Cancer and VHL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15586/jkcvhl.v10i3.242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管年龄小于46岁一直是遗传性肾细胞癌(hRCC)基因检测的独立标准,但在文献中缺乏证据。本研究旨在分析是否应将46岁的截止年龄视为独立的基因检测标准,并阐明预测基因检测阳性的危险因素。2010年1月至2021年12月的观察研究。所有年龄在46岁以下且有非转移性肾肿块和手术指征的患者均纳入研究。我们假设在前5年随访中复发的患者可能有阳性基因检测。作为复发的危险因素,因此基因检测阳性,我们考虑那些有多灶性、双侧或既往肾肿瘤的患者。在2232例因肾癌而行肾切除术的患者中,301例患者符合纳入标准。中位随访时间为60个月(IQR 29-101)。估计5年RFS为94.4% (95% CI 91.3-97.5)。肿瘤大小、既往肾肿瘤、多灶性、双侧、pT3或pT4分期是独立的复发危险因素。对24例患者进行基因检测。10名患者在测试中发现致病变异,其中8名患者在其一生中复发。46岁的截止年龄在基因检测中表现不佳。因此,我们建议只有在存在其他hRCC风险标准的情况下才考虑它。多灶性、双侧性和既往肾肿瘤可预测基因检测阳性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hereditary Renal Cell Carcinoma: Is Age an Independent Criterion for Genetic Testing? A Large Cohort from a Latin America Referral Center.

Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included. We assume patients who relapse in the first 5 years of follow-up could have a positive genetic test. As risk factors for relapse, ergo positive genetic test, we consider those patients who presented multifocal, bilateral, or previous renal tumor. Of 2,232 nephrectomies for kidney cancer, 301 patients met the inclusion criteria. The median follow-up was 60 months (IQR 29-101). The estimated five-year RFS was 94.4% (95% CI 91.3-97.5). Tumor size, previous renal tumor, multifocality, bilaterality, and pT3 or pT4 stage were independent recurrence risk factors. Genetic testing was performed on 24 patients. 10 patients had pathogenic variants in the test, 8 of which recurred during their life. 46-year-old cut-off has shown low performance in genetic testing. Therefore, we recommend that it be considered only if other hRCC risk criteria exist. Multifocality, bilaterality, and previous renal tumor could predict a positive genetic test.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
6.20%
发文量
22
审稿时长
4 weeks
期刊最新文献
Avoidable Benign Kidney Tumor Resections-Data from a Tertiary Care Cancer Institute. Primary Nonseminomatous Germ Cell Tumor of Kidney: An Uncommon Renal Neoplasm. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation (osteosarcomatous and chondrosarcomatous differentiation)-A Case Report and Comprehensive Review. An Uncommon Case of Sinonasal Adenoid Cystic Carcinoma Metastatic to the Kidney Treated with Metastasectomy. Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1